胆汁淤积性肝病治疗药物的临床研究进展

胆汁淤积性肝病是指由各种原因导致胆汁形成、分泌、排泄异常,从而引起肝脏发生病变。目前,治疗胆汁淤积性肝病的药物主要为熊去氧胆酸(UDCA),但近一半的患者对UDCA应答不充分或不耐受。这部分患者仅有奥贝胆酸(OCA)可用。随着近几年胆汁淤积性肝病的发病率明显上升,急需新型有效的治疗药物。临床研究表明,FXR激动剂、PPAR-α/γ激动剂和ASBT抑制剂能够有效改善胆汁淤积,有望成为新型胆汁淤积性肝病的临床治疗药物。针对以上靶点,对近几年较有前景的胆汁淤积性肝病治疗药物临床研究进展进行了综述,为此类药物的研究提供参考。

Progress in Clinical Research on Drug Therapy for Cholestatic Liver Disease

Cholestatic liver disease refers to the abnormal formation,secretion and excretion of bile caused by various reasons,resulting in liver lesions.Currently,ursodeoxycholic acid(UDCA) is the main drug used to treat cholestatic liver disease,but nearly half of patients have inadequate or intolerant response to UDCA.Only aubercholic acid(OCA) was available in these patients.With the increasing incidence of cholestatic liver disease in recent years,there is an urgent need for the development of new effective therapeutic drugs.Clinical studies have shown that FXR agonists,PPAR-α/γ agonists and ASBT inhibitors can effectively improve cholestasis and are expected to be used as therapeutic agents for the new type of cholestatic liver disease.Aiming at the above targets,this work reviews the promising clinical research progress in the treatment of cholestatic liver disease in recent years,so as to provide reference for the research of this kind of drugs.